IMCR NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Immunocore Holdings Ltd · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 33.81 USD
-3.4% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is 8.2% above the Trend Line and sits at 47.5% of its 52-week range. The latest completed week returned -3.4%, after a 4.0% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is volatility with 51/100 conviction, while the latest news-sentiment score is 52/100. Near-term considerations: volume confirmation is below normal; earnings are due in 4d.

Setup score 46 out of 100
Latest Close 33.81 USD 31 Jul 2026
1W Return -3.4% latest completed week
4W Return 4.0% short-term follow-through
12W Return 14.3% quarterly tape
Trend Breadth 44.2% 23 of 52 weeks active
Volume Ratio 0.7x vs 13-week average
What is working
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is weak, so confirmation is not yet broad enough.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -3.4% Latest completed week; four-week move 4.0%. Indicator stack 24/87 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Recent Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 51/100 conviction; expected move 17.9%. News sentiment 52/100 52 relevant articles in the latest sentiment read. Event risk 4d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is 8.2% above the Trend Line and sits at 47.5% of its 52-week range. The latest completed week returned -3.4%, after a 4.0% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.7x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.2812-week average 0.08

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure6/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.28Current proprietary activity-pressure read.
Buy signals1Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 4.0% over four weeks, 14.3% over 12 weeks, and 2.5% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-3.4%
4W4.0%
12W14.3%
26W3.9%
52W2.5%
Active trend streak0 weeks
Active weeks in one year23
Trend breadth44.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure1.36Latest activity-pressure read.
Pressure change160.8%Four-week change in activity pressure.
Leadership-6.00Latest relative-leadership reading.
RS change58.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 88% Model confidence 84%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength2/100Blend of value, momentum, and quality. Underlying universe rank 99; rank 1 is best.
Value6/100Relative valuation strength. Underlying universe rank 95; rank 1 is best.
Quality15/100Profitability and accounting quality. Underlying universe rank 86; rank 1 is best.
Momentum24/100Medium-term price momentum. Underlying universe rank 77; rank 1 is best.
Growth76/100Revenue and earnings growth. Underlying universe rank 25; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
4.6x
Market value relative to trailing revenue.
EV / EBITDA
282.6x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-1.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
98.8%
Gross profit retained from each unit of revenue.
Operating margin
0.8%
Operating profit retained from revenue.
Free-cash-flow margin
-4.9%
Free cash flow generated from revenue.
Return on invested capital
0.6%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
15.6%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-152.8%
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.6%
Net share repurchases relative to market value.
Shareholder yield
-0.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-2.7x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

IMCR shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 17.9%, and Sharemaestro trend signal inactive.

Conviction51/100
Expected move17.9%
Put/call volume0.00
Pressure100
Speculation5
Volatility81
Trend agreement0
Open options detail
Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 52 relevant articles.

9 positive · 40 neutral · 3 negative
Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings4dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move17.9%Nearest-chain priced movement where available.
52-week drawdown-17.0%Distance below the 52-week high.
13-week volatility4.3%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+9.4%Week of 17 Jul.
Worst week-6.8%Week of 24 Apr.
Latest week-3.4%Week of 31 Jul.

Shape of recent returns

Strong gains5
Modest gains9
Flat weeks0
Modest losses9
Sharp losses3
Recent vol4.3%13-week weekly-return volatility.
Base vol4.7%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew3.6% / -3.5%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape42/100

Trend, activity pressure, participation, and risk combine to a 42/100 tape read.

 Indicator analysis24/100

Latest 12-week confirmation: trend 0/12, activity pressure 6/12, relative leadership 0/12.

Activity pressure 0.28; No reversal markers Factors10/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 76; Small Cap Core rank 93 Patient CapitalRecent

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

Recent buy signal in the last 8 weeks Options35/100

IMCR shows volatility options pressure with a 51/100 conviction score, put-call volume ratio of 0.00, expected move of 17.9%, and Sharemaestro trend signal inactive.

Volatility · Volatility expansion watch · Expected move 17.9% Sentiment52/100

Weighted news tone is neutral across 52 relevant articles.

Mizuho Lifts Price Target on Immunocore Holdings to $35 From $34, Keeps Neutral Rating Insiders50/100

No recent insider transaction evidence is stored.

 Earnings4d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202633.81 USD-3.4%31.25 USD39.91 USD1.36-6.001.7MOff
24 Jul 202635.00 USD0.1%31.25 USD40.10 USD1.44-2.542.7MOff
17 Jul 202634.96 USD9.4%31.29 USD40.30 USD1.41-4.593.8MOff
10 Jul 202631.95 USD-1.7%31.32 USD40.49 USD0.96-16.883.0MOff
3 Jul 202632.50 USD5.2%31.48 USD40.69 USD0.52-14.522.9MOff
26 Jun 202630.88 USD8.0%31.69 USD40.88 USD0.09-18.494.5MOff
19 Jun 202628.60 USD-1.2%31.98 USD41.07 USD-0.39-28.252.0MOff
12 Jun 202628.96 USD2.4%32.34 USD41.27 USD-0.55-25.961.8MOff
5 Jun 202628.29 USD-2.1%32.57 USD41.47 USD-0.75-26.682.7MOff
29 May 202628.89 USD0.2%32.74 USD41.65 USD-0.92-29.252.1MOff
22 May 202628.83 USD2.8%32.88 USD41.83 USD-1.05-28.142.0MOff
15 May 202628.05 USD-5.2%33.03 USD42.01 USD-1.13-29.75786.1KOff
8 May 202629.58 USD5.0%33.21 USD42.20 USD-0.95-26.631.5MOff
1 May 202628.16 USD-3.9%33.30 USD42.40 USD-0.85-26.732.3MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.